Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8)
Pediatric Nephrology · 2025
DOI: 10.1007/s00467-025-06675-8 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Pediatric Nephrology, 2025. Verfasst von David J Sas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Sas.David@mayo.edu. Hauptthemen laut MEDLINE: Hyperoxaluria, Primary, L-Lactate Dehydrogenase. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Dicerna Pharmaceuticals, Inc., Novo Nordisk Company (Lexington, MA, USA).
Abstract (Originalsprache)
Background
Primary hyperoxaluria type 1 (PH1) is an autosomal recessive disorder with dysregulated glyoxylate metabolism in the liver. Oxalate over-production leads to renal stones, progressive kidney damage and renal failure, with potentially life-threatening systemic oxalosis. Nedosiran is a synthetic RNA interference therapy, designed to reduce hepatic lactate dehydrogenase (LDH) to decrease oxalate burden in PH.
Methods
Currently, in the PHYOX8 study (NCT05001269), pediatric participants (2–11 years) with PH1 ( N = 15) and estimated glomerular filtration rate (eGFR) ≥ 30mL/min/1.73m 2 received nedosiran once monthly for 6 months.
Results
Urinary oxalate:creatinine (Uox:Ucr) levels reduced by 64% on average. Mean Uox:Ucr reduction was 52% at day 60 and ˃60% at day 180. At one or more study visits, 93.3% ( N = 14) of participants reached Uox:Ucr < 1.5 × upper limit of normal (ULN), and 53.3% ( N = 8) reached ≤ 1.0 × ULN. Median percent change in plasma oxalate (12.0 µmol/L at baseline) to day 180 was –39.23% ( n = 10). Average number of kidney stones per participant remained stable, whilst a 10.1% average decrease in summed surface area was observed. Median percent change from baseline in eGFR was 2.5%, indicating preservation of renal function.
Conclusions
Nedosiran was well tolerated, with only 3 participants experiencing at least one serious adverse event, none considered treatment-related. The incidence of injection site reactions was 6.7% (1/15 participants). In conclusion, nedosiran treatment led to a significant and sustained reduction of Uox levels in children with PH1. These findings support nedosiran treatment in pediatric patients to reduce Uox and shows promise for limiting PH1-related complications. Graphical abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pediatric Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Sas.David@mayo.edu.
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA. Sas.David@mayo.edu.
- Division of Nephrology and Hypertension, Mayo Clinic, Rochester, MN, USA. Sas.David@mayo.edu.
- Department of Pediatric Nephrology, Gazi University, Ankara, Turkey.
- Department of Pediatrics, McMaster Children's Hospital, Hamilton, Canada.
- Department of Pediatric Nephrology, Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK.
Förderung
- Dicerna Pharmaceuticals, Inc.
- Novo Nordisk Company (Lexington, MA, USA)
Zitieren
APA
Sas, D. J., Bakkaloglu, S. A., Belostotsky, V., Hayes, W., Ariceta, G., Zhou, J., & Rawson, V. (2025). Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8). Pediatric Nephrology. https://doi.org/10.1007/s00467-025-06675-8
Vancouver
Sas DJ, Bakkaloglu SA, Belostotsky V, Hayes W, Ariceta G, Zhou J, et al. Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8). Pediatric Nephrology. 2025. doi:10.1007/s00467-025-06675-8
BibTeX
@article{Sas2025,
author = {Sas, David J and Bakkaloglu, Sevcan A and Belostotsky, Vladimir and Hayes, Wesley and Ariceta, Gema and Zhou, Jing and Rawson, Verity},
title = {Nedosiran in pediatric patients with PH1 and relatively preserved kidney function, a phase 2 study (PHYOX8)},
journal = {Pediatric Nephrology},
year = {2025},
doi = {10.1007/s00467-025-06675-8}
}
EUVIMED